SERPINE1 and COVID-19: Although interesting evidence is emerging especially for PAI-1 in COVID-19 [30], its measurement is limited by large inter-laboratory variability, which is attributable to the different assay methodology, antigenic specificity of the antibodies, the lack of internationally certified calibrators and quality controls, as well as to the many measuring units that can be used for reporting data.